Press release
ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer
ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need.
Image: https://www.globalnewslines.com/uploads/2025/07/5b4b64d3d25a93a3b2f4f1dadf688558.jpg
These positive developments highlight the significant market potential of ISOT-101 in the NERD PPI-PR segment, an estimated 15-30 million patients in the U.S alone who are inadequately addressed by current gold standard therapies and a multi-billion-dollar annual company market opportunity.
In light of this clinical and commercial potential, long-time ISOThrive board member and pharmaceutical industry veteran Mike Walther will expand his role as Chief Strategy Officer. Mr. Walther's 30+ year gastroenterology experience, including the launch of and key leadership roles on blockbuster heartburn medications, Prevacid Registered and Dexilant Registered , will be leveraged to accelerate the company's next stage opportunities, including strategic partnerships and/or M&A.
"This encouraging interim data supports our novel approach and strengthens our development program," said Jack Oswald, CEO. "Our treatment shows the potential to become a leading solution for millions of NERD patients who remain symptomatic despite current treatment options. We believe this progress positions us for a high-value strategic transaction. Bringing a seasoned executive like Mike Walther on board is a critical step in capitalizing on this momentum."
Mike Walther, Chief Strategy Officer, added, "The interim data for ISOT-101 is exceptionally encouraging, suggesting a meaningful impact in a patient population that remains symptomatic with current options. Having been involved with two of the most successful PPIs, I am thrilled to now work even more closely with the executive team at this pivotal moment to help realize the immense potential of this product and accelerate our path forward for a non-acid suppressing, first-of-it's kind microbiome-targeting therapy ."
Study completion scheduled for Q4 2025.
ISOThrive Inc. is developing novel, microbiome-targeted therapeutics for gastrointestinal diseases. Its lead product, ISOT-101, with over 30 global patents, is a first-in-class treatment being evaluated for Non-Erosive Reflux Disease (NERD). ISOThrive.com
Acid Reducing Medications: Omeprazole (Prilosec Registered : AstraZeneca Procter&Gamble, Zegerid Registered : Riley), Esomeprazole (Nexium Registered : AstraZeneca), Lansoprazole (Prevacid Registered : Takeda), Dexlansoprazole (Dexilant Registered : Takeda), Pantoprazole (Protonix Registered : Pfizer), Rabeprazole (Aciphex Registered : Waylis), Vonoprazan (Voquezna Registered : Phathom).
Media Contact
Company Name: ISOThrive Inc
Contact Person: Jack Oswald
Email: Send Email [http://www.universalpressrelease.com/?pr=isothrive-announces-promising-phase-2-interim-data-for-novel-heartburn-treatment-and-appoints-pharma-veteran-mike-walther-as-chief-strategy-officer]
Phone: 415-272-6200
Address:2165 Toyon Drive
City: Healdsburg
State: CA
Country: United States
Website: http://ISOThrive.com
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer here
News-ID: 4088712 • Views: …
More Releases from Getnews
COOFANDY Black Friday and Cyber Monday: Discounts on Quality Men's Winter Wear
COOFANDY Black Friday And Cyber Monday: Quality Men's Winter Wear, 15% Off Early Access!
Say goodbye to the mediocre and take control of your style. Men's fashion brand COOFANDY is the first to ignite the winter shopping season, officially announcing the launch of its Black Friday and Cyber Monday event-"The Holiday Season of Glow." Facing the cold and upcoming holiday gatherings, we don't have to compromise between style and warmth. COOFANDY…
Zeagoo Launches "The Holiday Season of Glow": Black Friday and Cyber Monday to L …
The overture to winter has begun, and the brilliant glow of the holidays is gradually lighting up the streets. Global women's apparel brand Zeagoo is thrilled to officially announce the launch of its biggest shopping extravaganza of the year-"The Holiday Season of Glow"-aimed at injecting confidence and sparkle into every woman's winter look with items that blend comfort and fashion. Our campaign slogan is: "Dress in your festive sparkle," inviting…
Mark M Winkler Inspires Young Readers with Life Lessons Through Fly Fishing
Image: https://www.globalnewslines.com/uploads/2025/11/1763154989.jpg
Image: https://www.aionewswire.com/storage/images/ckeditor//Mark%20pic_1763152992.png
Author Mark M. Winkler [https://markmwinkler.com/] invites readers on a heartwarming and insightful journey with his new children's book, Life Lessons Through Fly Fishing . Blending the beauty of nature with timeless wisdom, Winkler crafts a story that teaches children valuable lessons in patience, compassion, and humility.
Image: https://www.aionewswire.com/storage/images/ckeditor//Life%20Lessons%20Through%20Fly%20Fishing_1763153468.jpg
Life Lessons Through Fly Fishing [https://www.amazon.com/Life-Lessons-Through-Fly-Fishing/dp/B0BPGG6CXK/ref] follows the journey of two children and their father as they set out on a meaningful…
Apple Roofing Kearney Strengthens Storm Recovery Services with New Wind Damage R …
Image: https://www.globalnewslines.com/uploads/2025/11/1763161611.jpg
Kearney, NE - November 15, 2025 - Apple Roofing in Kearney [https://appleroof.com/kearney/], Nebraska, has officially announced the rollout of advanced roofing inspection and repair technology aimed at enhancing its wind damage response services. As Nebraska continues to experience increasingly volatile weather conditions, the company's latest investment in high-efficiency tools and inspection equipment positions it to meet rising demand for storm-related roofing repairs.
Known for its high standards and customer-first service,…
More Releases for ISOThrive
Animal Microbiome Market Latest Trends and Growth Factors Analysis 2024 to 2031
Animal Microbiome Market worth $12.4 Billion by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd.'s recently published report, "Global Animal Microbiome Market- By Trends, Industry Competition Analysis, Revenue (US$ Millions) and Forecast Till 2030," provides an in-depth analysis and comprehensive study of the market, examining its key factors.
Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/1046
According to the most recent market intelligence research report by InsightAce…
Functional Dyspepsia Market Size is Set for Rapid Growth as Innovative Treatment …
The Functional Dyspepsia market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, RaQualia Pharma Inc,Renexxion LLC, Zeria Pharmaceutical Co Ltd., GlaxoSmithKline, Abbott, Dexa Medica Group, Astellas Pharma Inc, Eisai Co., Ltd., Forest Laboratories, Novartis, Bayer
[Nevada, United States] - DelveInsight's "Functional Dyspepsia Market Insights,…
Functional Dyspepsia Market Forecasts by DelveInsight Signal Groundbreaking Grow …
DelveInsight's "Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Functional Dyspepsia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The market report covers emerging drugs, treatment practices, market share of individual Functional Dyspepsia therapies, and current & forecasted…
Animal Microbiome Market Survey Detailed Analysis and Forecast 2023-2031
The newly published report titled "Global Animal Microbiome Market- By Trends, Industry Competition Analysis, Revenue (US$ Millions) and Forecast Till 2030." of InsightAce Analytic Pvt. Ltd. features in-depth analysis and an extensive study on the market, exploring its significant factors.
The Animal Microbiome Market Size is valued at 6241.41 Million in 2022 and is predicted to reach 13687.71 Million by the year 2031 at a 9.2 % CAGR during the forecast…
Dyspepsia Market to Grow Rapidly During the Forecast Period (2019-2032) -DelveIn …
DelveInsight's Dyspepsia Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Dyspepsia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Dyspepsia Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size from 2019 to…
Human Microbiome Modulators Market Analysis By Type, Application, Growth, Demand …
Worldwide Human Microbiome Modulators Market 2022 Research Report presents a professional and complete analysis of the Global Human Microbiome Modulators Market on the current situation. This report includes development plans and policies along with Human Microbiome Modulators manufacturing processes and price structures. the reports 2022 research report offers an analytical view of the industry by studying different factors like Human Microbiome Modulators Market growth, consumption volume, Market Size, Revenue,…
